Literature DB >> 8823092

Use of the radial artery for myocardial revascularization.

E Manasse1, G Sperti, H Suma, C Canosa, A Kol, L Martinelli, R Schiavello, F Crea, A Maseri, G F Possati.   

Abstract

BACKGROUND: The radial artery was first used as a coronary graft by Carpentier and associates in 1973 but, due to the disappointing results, it was abandoned. In 1992 its revival coincided with the widespread use of calcium-channel blockers in cardiovascular surgery, in the belief they could prevent spasm.
METHODS: From January 1993 to October 1995 we operated on 109 patients for myocardial revascularization employing the radial artery with two different surgical techniques: in 95 patients (group 1) it was "pretreated" by opening its fascia after a gentle hydrostatic dilation and then anastomosed to the aorta; in 14 patients (group 2) it was branched to another conduit. We had two operative deaths (1.82%).
RESULTS: At a mean interval of 532.42 days 105 patients are still alive, 2 (1.86%) having died of abdominal tumors. Fifty-six patients (52.33%) underwent angiography at a mean interval of 334.42 days: the patency of the radial artery was 88.88% in group 1 and 62.50% in group 2. Indications and contraindications are discussed.
CONCLUSIONS: The radial artery is an easily manageable conduit whose early patency is very promising, although a longer follow-up is mandatory.

Entities:  

Mesh:

Year:  1996        PMID: 8823092     DOI: 10.1016/0003-4975(96)00594-2

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  2 in total

Review 1.  The Use of Radial Artery for CABG: An Update.

Authors:  Francesco Nappi; Francesca Bellomo; Pierluigi Nappi; Camilla Chello; Adelaide Iervolino; Massimo Chello; Christophe Acar
Journal:  Biomed Res Int       Date:  2021-04-07       Impact factor: 3.411

2.  The radial artery as a coronary bypass conduit: dealing with hypereactivity.

Authors:  Suleiman Kharabsheh; Zohair Al-Halees
Journal:  Ann Saudi Med       Date:  2005 Jan-Feb       Impact factor: 1.526

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.